Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Other financing activities (2021 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Other financing activities data on record, last reported at $7.5 million in Q4 2023.

  • For Q4 2023, Other financing activities fell 73.11% year-over-year to $7.5 million; the TTM value through Dec 2023 reached $30.4 million, down 37.11%, while the annual FY2025 figure was $36.0 million, 4.72% down from the prior year.
  • Other financing activities reached $7.5 million in Q4 2023 per CGEM's latest filing, down from $7.7 million in the prior quarter.
  • Across five years, Other financing activities topped out at $28.0 million in Q4 2022 and bottomed at -$5.0 million in Q3 2021.
  • Average Other financing activities over 4 years is $7.9 million, with a median of $7.4 million recorded in 2023.
  • Peak YoY movement for Other financing activities: skyrocketed 205.74% in 2022, then tumbled 73.11% in 2023.
  • A 4-year view of Other financing activities shows it stood at $13.7 million in 2020, then crashed by 136.38% to -$5.0 million in 2021, then skyrocketed by 660.82% to $28.0 million in 2022, then crashed by 73.11% to $7.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $7.5 million in Q4 2023, $7.7 million in Q3 2023, and $7.9 million in Q2 2023.